GMED News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GM

Mkt Cap

$10.30B

Volume

1.74M

Next Earnings

November 5th

Loading chart

GM

GMEDGLOBUS MEDICAL INC

GMED

Pay with—

Available Balance0.00

GM

Mkt Cap

$10.30B

Volume

1.74M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

GMED or AXGN: Which Is the Better Value Stock Right Now?In a comparison of two medical instruments stocks, Globus Medical (GMED) and AxoGen (AXGN), both holding a Zacks Rank #2 (Buy), GMED emerges as the superior value option. GMED has a forward P/E of 15.81 compared to AXGN's 73.46, a PEG ratio of 1.27 vs 1.42, and a P/B ratio of 2.22 vs 7.47, earning GMED a Value grade of B while AXGN received an F.Zacks Investment Research · Oct 16, 2026

Reasons to Add STE Stock to Your Portfolio Right NowSTERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.Zacks Investment Research · Oct 16, 2026

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.Zacks Investment Research · Oct 16, 2026

Is it Apt to Retain Medtronic Stock in Your Portfolio Now?Medtronic is expanding its presence in high-growth markets including cardiac ablation (up 88%), robotics, and structural heart, while advancing the MiniMed separation. The company is building its hypertension business through the Symplicity Spyral renal denervation franchise with improved reimbursement and clinical evidence. However, Medtronic faces headwinds from tariffs, inflation, currency fluctuations, and unfavorable product mix that could pressure margins.Zacks Investment Research · Oct 16, 2026

BD's Revello Stent Shows Strong AGILITY Trial Results for PAD PatientsBecton, Dickinson and Company (BD) announced positive nine-month results from the AGILITY trial for its Revello Vascular Covered Stent in treating iliac artery disease. The trial met its primary endpoint with a 2.8% failure rate, 97.2% primary patency, and 98.3% freedom from clinically driven target lesion revascularization. The device remains investigational in the U.S. with clinical follow-up continuing through 36 months. The global iliac stent market is projected to grow at a 6.5% CAGR through 2033.Zacks Investment Research · Oct 15, 2026

Doximity Deepens U.S. News Alliance to Improve Patient Access to CareDoximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date.Zacks Investment Research · Oct 15, 2026

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average.Zacks Investment Research · Oct 15, 2026

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million.Zacks Investment Research · Oct 14, 2026

BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026?BrightSpring Health Services (BTSG) has surged 67.3% year-to-date, outperforming broader markets, driven by strong growth in Specialty and Infusion revenues (up 32.7%) and Provider Services (up 29.1%). The company raised its 2026 outlook twice and improved leverage to 2.15x after divesting its Community Living business. However, a $200M IRA impact on Home and Community Pharmacy and integration execution risks present headwinds. Analysts rate BTSG as a Hold.Zacks Investment Research · Oct 14, 2026

Reasons to Add QuidelOrtho Stock to Your Portfolio for NowQuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season.Zacks Investment Research · Oct 14, 2026

to start trading

GM

GMEDGLOBUS MEDICAL INC

GMED

Pay with—

Available Balance0.00

Your PositionYou don't own any GMED yet.

Related Tickers

Earnings